Follow-up in all patients:
Two patients (1.1%) were deceased during the 30-day FU, due to cardiovascular causes. The six-month all-cause mortality rate was 8.5% (n=15) and the 12-month all-cause mortality rate was 23.4% (n=41).
At six-month FU, we found significantly improved NHYA functional class (NYHA>II: 100% to 31.66%, p=0.001) and increased six-minute walk distance (247.23±33.4 m to 333.45±60.5 m, p=0.001) in the overall cohort.
Echocardiography at six-month FU showed no significant changes in LV dimensions and function (LV-EDV: group 1, p=0.6 vs group 2, p=0.3; LV-ESV: group 1, p= 0.4 vs group 2, p= 0.5; LV-EF: group 1, p=0.5 vs group 2, p=0.9). We found a significant and sustained reduction in MR for the overall cohort six months after the procedure (MR >II; 91.36% to 2.48%, p<0.001).Moreover, RVSP significantly decreased within the six-month FU period (45.4±14.8 mmHg, 34.7±10.5 mmHg, p= 0.01).